Development of fluorizoline analogues as prohibitin ligands that modulate C-RAF signaling, p21 expression and melanogenesis.
Cancer
Heterocycles
MAP kinases
Melanogenesis
Prohibitins
p21
Journal
European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510
Informations de publication
Date de publication:
15 Nov 2022
15 Nov 2022
Historique:
received:
27
05
2022
revised:
25
07
2022
accepted:
25
07
2022
pubmed:
22
8
2022
medline:
21
9
2022
entrez:
21
8
2022
Statut:
ppublish
Résumé
Fluorizoline is a cytotoxic trifluorothiazoline that targets the scaffold proteins prohibitins-1 and -2 (PHB1/2) to inhibit the kinase C-RAF and promote the expression of the cyclin-dependent kinase inhibitor p21 to induce cancer cell death. In melanocytes, fluorizoline also induces the synthesis of melanin. Herein we report the first structural requirement of fluorizoline analogues for these activities. We identified in particular some compounds that display enhanced anti-C-RAF and anti-MEK activities, and a higher cytotoxicity in HeLa cells compared to fluorizoline. These results provide a foundation for further optimization of PHB ligands for the treatment of cancers. We also discovered an analogue of fluorizoline that displays pharmacological effects opposed to those of fluorizoline and that can be used as a chemical tool to explore PHB signaling in cancers and other diseases.
Identifiants
pubmed: 35988448
pii: S0223-5234(22)00537-2
doi: 10.1016/j.ejmech.2022.114635
pii:
doi:
Substances chimiques
Cyclin-Dependent Kinase Inhibitor p21
0
Ligands
0
Melanins
0
Prohibitins
0
Proto-Oncogene Proteins
0
Repressor Proteins
0
Transcription Factors
0
Protein Serine-Threonine Kinases
EC 2.7.11.1
Proto-Oncogene Proteins c-raf
EC 2.7.11.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
114635Informations de copyright
Copyright © 2022. Published by Elsevier Masson SAS.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.